00:00The contribution of Otsuka in oncohematology is extremely important as it is developing new oral medicines that can be therapeutic alternatives for patients affected by acute myeloid leukemia.
00:20These patients have an unmet medical need and this contribution of innovation will allow to improve both the survival and the quality of life of patients affected by acute myeloid leukemia.
00:38In clinical practice, many oral medicines have been introduced in oncohematology in the last 30 years. Some of these have significantly changed the prognosis of patients affected by oncohematological pathologies and in recent years we have also tried to improve the quality of life of these patients, which is another extremely relevant parameter.
01:02The innovation brought by Otsuka focuses mainly on patients affected by acute myeloid leukemia, which are patients with an extremely aggressive disease and a prognosis in fausta,
01:16to which having a completely effective oral alternative allows, on the one hand, to have a further option of treating their pathology and, on the other, to have an attention to their quality of life.
Comments